Clinical trials for first lung cancer vaccine underway. Where in Va. and Md. is it being tested

The first vaccine that aims to kill the most common form of lung cancer and keep it from coming back is being tested in Maryland and Virginia as part of a global clinical trial.

Known as BNT116, and made by German biotechnology company BioNTech, the vaccine targets non-small cell lung cancer, or NSCLC, the most common type of lung cancer.

Unlike vaccines to prevent viruses, BNT116 is designed to eliminate cancer cells and prevent recurrence, by training the immune system to recognize...